16:42 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

AZ says Phase IIIb data of Bevespi Aerosphere in COPD are 'inconsistent with previous data'

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Bevespi Aerosphere glycopyrrolate/formoterol fumarate met one of three primary endpoints in the Phase IIIb AERISTO trial to treat moderate to very severe chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere was...
15:19 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Cell culture and mouse studies suggest inhibiting GRK2 could help treat influenza A infection. In a human alveolar basal epithelium cell line infected with human or avian strains of influenza A, an siRNA...
23:07 , Sep 19, 2018 |  BC Extra  |  Company News

Management tracks: GSK adds Corsico, Enzmann to chair CHMP

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) hired Chris Corsico, CMO of Boehringer Ingelheim GmbH (Ingelheim, Germany), to lead all development activities for the pharma. As SVP development, Corsico will be based at GSK’s R&D hub in Stevenage,...
23:29 , Sep 17, 2018 |  BC Extra  |  Politics & Policy

FDA to re-examine diabetes CVOT requirements

FDA is reconsidering its policy to require pre- and postmarket cardiovascular outcomes trials for diabetes drugs, and plans to hold an Oct. 24-25 meeting of its Endocrinologic and Metabolic Drugs Advisory Committee to discuss existing...
22:10 , Sep 17, 2018 |  BC Extra  |  Company News

Management tracks: Ultragenyx, Epizyme

Rare and ultra-rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) appointed Wladimir Hogenhuis as COO. Previously, he was SVP and general manager, specialty franchise at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Epizyme Inc. (NASDAQ:EPZM) said CBO Susan Graf will...
19:49 , Sep 14, 2018 |  BC Week In Review  |  Company News

Telo, GSK targeting TERT to halt glioblastoma cell immortality

Telo Therapeutics Inc. (San Francisco, Calif.) is exploiting a partnership with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to discover small molecules against an isoform of GABPB1, first identified as a cancer immortality target in a paper published...
17:29 , Sep 14, 2018 |  BC Week In Review  |  Financial News

Xenon further strengthens balance sheet with $63M follow-on

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) raised $63 million through the sale of 4.5 million shares at $14 in a follow-on underwritten by Jefferies and Stifel. The price is a 2% discount to Xenon's closing price of $14.25...
22:42 , Sep 13, 2018 |  BC Week In Review  |  Clinical News

FDA needs more data to support GSK's Nucala for COPD

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) received a complete response letter from FDA to an sBLA for Nucala mepolizumab to treat chronic obstructive pulmonary disease. According to the pharma, the agency said more clinical data are required...
14:30 , Sep 13, 2018 |  BC Extra  |  Financial News

Xenon further strengthens balance sheet with $63M follow-on

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) raised $63 million through the sale of 4.5 million shares at $14 in a follow-on underwritten by Jefferies and Stifel. The price is a 2% discount to Xenon's closing price of $14.25...
22:17 , Sep 7, 2018 |  BC Extra  |  Company News

FDA needs more data to support Nucala for COPD

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) received a complete response letter from FDA to an sBLA for Nucala mepolizumab to treat chronic obstructive pulmonary disease. According to the pharma, the agency said more clinical data are required...